Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) ...

RECLAIM - LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe ...

The EvoLVcell stable producer cell line generation platform reportedly reduces variability and produces fewer impurities.

ACROBiosystems has upgraded its global license solution for HEK293 functional cell lines to expedite biopharmaceutical R&D.

ACROBiosystems has implemented a major upgrade to its global licensing framework for HEK293 functional cell lines, ...

Researchers have identified a previously unknown cell type hidden on the roots of common beans, a microscopic survival mechanism that could inform the development of more climate-resilient crops and ...

Now, it’s worth noting Stock Advisor’s total average return is 963 % — a market-crushing outperformance compared to 201% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

Successful partnership continues as bispecific antibody candidate moves to GMP manufacturing; project highlights Japan's advanced capabilities in bioprocessing and AGC Biologics' expanding global ...

The upcoming Solar Manufacturing USA 2026 conference in Austin will focus on real U.S. solar manufacturing progress, shifting attention from capacity announcements to actual production, costs, yields, ...

The field of infectious disease research faces persistent challenges in bridging the gap between laboratory findings and successful clinical translation.